SARS-CoV-2 /COVID-19 Admission Screening in a University Hospital Setting

Covid19 Clinical Trial

Official title:

SARS-CoV-2 /COVID-19 Admission Screening in a University Hospital Setting (Covid-Screen Quality Control Study)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04519372
• Other study ID #: 2020-00808
• Status: Completed
• Start date: April 1, 2020
• Est. completion date: March 31, 2021

Study information

• Verified date: May 2021
• Source: University Hospital, Basel, Switzerland
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The proportion of asymptomatic carriers of SARS-CoV-2 remains elusive, so the potential benefit of systematic screening during the SARS-CoV-2-pandemic is controversial. We investigate the proportion of asymptomatic inpatients who were identified by systematic screening for SARS-CoV-2 upon hospital admission.

Adult patients admitted to the University Hospital Basel from 01.04.-14.06.2020 were routinely tested for SARS-CoV-2 within 72 hours of admission by nasopharyngeal swabs.

Each patient screened during the study period was retrospectively classified symptomatic or asymptomatic for COVID-19 based on medical chart review.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 4099
• Est. completion date: March 31, 2021
• Est. primary completion date: June 14, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• The patient population is defined as all adult patients hospitalized in the University Hospital Basel from April 1st, 2020 to June 14th, 2020.

Exclusion Criteria:

• Outpatients

• Patients with SARS-CoV-2 screening in the outpatient test center

• Patients with a SARS-CoV-2 test more than 72 hours before hospital admission

• Test not performed (for any reason)

Related Conditions & MeSH terms

• Covid19
• SARS-CoV-2

Intervention

Diagnostic Test:
• Testing for SARS-CoV-2
All Patients admitted to the hospital were routinely tested for SARS-CoV-2 within 72 hours of admission by nasopharyngeal swabs.

Locations

Country	Name	City	State
Switzerland	University Hospital Basel, Division of Infectious Diseases and Hospital Epidemiology	Basel

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Basel, Switzerland

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of SARS-CoV-2 -infected patients	We aim to determine the proportion of SARS-CoV-2-infected patients detected by systematic at-admission screening	01.04.2020-14.06.2020